United Therapeutics Corp
Research United Therapeutics Corp (UTHR) on Bullrun: valuation model: 2.8% undervalued, market cap USD 23.44B, P/E 19.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerUTHR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal2.8% undervalued
- Market capUSD 23.44B
- P/E19.6
- Financial periodQ2 2026
- RevenueUSD 783.30M
- Net incomeUSD 333.00M
- Free cash flowUSD 205.60M
- Gross margin87.3%
Valuation Snapshot
Bullrun's latest valuation model marks United Therapeutics Corp as 2.8% undervalued; latest market cap is USD 23.44B; P/E is 19.6.
Peer valuation comparison
Latest P/E is 19.64x versus a Healthcare sector median of 24.61x (20.2% below).
Latest P/E is 19.64x versus a United States median of 23.85x (17.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.18B | USD 1.33B | USD 1.04B | 87.9% | 27.86 | USD 1.56B | USD 200.00M | USD 7.10B |
| FY2024 | USD 2.88B | USD 1.20B | USD 1.08B | 89.2% | 24.64 | USD 1.70B | USD 300.00M | USD 6.44B |
| FY2023 | USD 2.33B | USD 984.80M | USD 747.60M | 88.9% | 19.81 | USD 1.21B | USD 700.00M | USD 5.98B |
| FY2022 | USD 1.94B | USD 727.30M | USD 663.70M | 92.2% | 15 | USD 961.20M | USD 800.00M | USD 4.80B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 23.44B | 19.6 | n/a | n/a |
| 2025 | 2025-12-31 | USD 21.27B | 17.5 | n/a | n/a |
| 2024 | 2024-12-31 | USD 15.82B | 14.3 | n/a | n/a |
| 2023 | 2023-12-29 | USD 10.33B | 12.1 | n/a | n/a |
| 2022 | 2022-12-30 | USD 12.67B | 18.9 | n/a | n/a |
| 2021 | 2021-12-31 | USD 9.75B | 21.6 | n/a | n/a |
About United Therapeutics Corp
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise;
ETFs that hold United Therapeutics Corp
United Therapeutics Corp is one of the ten largest holdings of 4 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| State Street SPDR S&P 400 US Mid Cap UCITS ETF | 0.69% | 0.30% |
| WisdomTree BioRevolution UCITS ETF - USD Acc | 2.52% | 0.45% |
| State Street SPDR S&P 400 US Mid Cap UCITS ETF USD Unhedged (Dist) | 0.69% | 0.30% |
| State Street SPDR S&P 400 US Mid Cap UCITS ETF EUR Hedged (Dist) | 0.69% | 0.35% |
Related stock research
Other Healthcare stocks
Frequently asked questions
Is United Therapeutics Corp overvalued or undervalued?
Bullrun's valuation model currently marks United Therapeutics Corp as 2.8% undervalued.
What is United Therapeutics Corp's market cap?
United Therapeutics Corp's market capitalization is USD 23.44B.
What is United Therapeutics Corp's P/E ratio?
United Therapeutics Corp's price-to-earnings (P/E) ratio is 19.6.
What does United Therapeutics Corp do?
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.